Uncategorized Archives - Page 3 of 146

MondayNov 03, 2025 12:00 pm

Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium

The company revealed the trial at the Australia Translational Breast Cancer Research Symposium (“ATBCR”) Sapu-003 is an injectable formulation of Everolimus (Afinitor(R)), which aims to offer higher bioavailability and better efficacy than oral versions of the drug The trial is conducted alongside partners like the Southern Oncology Clinical Research Unit (“SOCRU”), Ingenū, and Medicilon Sapu Nano, which is in the Sapu family of companies, which was through GMP Biotechnology Limited, a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently revealed the company’s first in-human clinical trial of Sapu-003. The announcement occurred at the Australian Translational Breast Cancer Research…

TuesdayOct 28, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability

Thermostable vaccine technology is considered a significant unmet need in epidemic preparedness. Soligenix has been developing formulations intended to remain stable even when stored for extended periods at temperatures above 40°C. Soligenix’s ThermoVax(R) technology has broad applicability in Emerging Infectious Disease. Current vaccines for Ebola and similar filoviruses face a major deployment barrier: Most require storage between 2°C and 8°C throughout transport, making them vulnerable to spoilage when exposed to the high ambient heat common in many outbreak regions (https://ibn.fm/MZWfk). Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines, has published a peer-reviewed summary of new…

WednesdayOct 22, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Breast Cancer Awareness Month by Addressing Gaps in Screening and Advancing the IzoView Breast CT Solution

Izotropic highlights recurrent challenges in current breast imaging technologies and the need for high-resolution, true 3D imaging The IzoView breast CT scan technology is created for accurate, compression-free imaging for women who have dense breast tissue Increased screening demands and regulatory momentum underscore the opportunities for dedicated breast CT solutions IZOZF’s innovative approaches highlight the company’s mission to improve diagnosis, detection, and care for people globally Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device firm leading imaging-based solutions for better diagnosis, screening, and treatment of breast cancer patients, is bringing the challenges of current screening systems and the…

TuesdayOct 21, 2025 9:00 am

Nanomedicine’s Next Leap: Why Particle Size Matters in Cancer Drug Delivery

Sapu003 Phase 1 trial begins: Australian HREC approval validates Oncotelic’s proprietary 20nm nanoparticle technology for enhanced breast cancer drug delivery 20nm Deciparticle(TM) achieves full bioavailability: Intravenous delivery of Everolimus (Afinitor(R)) maximizes tumor targeting and efficacy compared to 10% absorption with oral formulations Rapid IND platform accelerates pipeline: Strategic partnership with Medicilon supports up to 20 IND projects, shortening development timelines and enabling multiple Deciparticle(TM) drug candidates to reach clinical testing quickly Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing precision nanomedicine with its proprietary Deciparticle(TM) platform, beginning human trials for Sapu003, a 20nm nanoparticle formulation of Everolimus (Afinitor(R)). This scientific briefing explores…

ThursdayOct 16, 2025 9:45 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV ketamine formulation. The filing follows FDA approval of the company’s Suitability Petition to remove benzethonium chloride (“BZT”), a preservative linked to neurotoxicity. In parallel, NRx is advancing NRX-100, another preservative-free ketamine formulation under a New Drug Application (“NDA”) for suicidal ideation in depression, including bipolar depression. NRX-100 holds Fast Track Designation and may qualify for the FDA’s National Priority Voucher Program. The company also continues work on NRX-101, a Breakthrough Therapy for suicidal bipolar depression. CEO Dr. Jonathan Javitt recently discussed new pipeline developments and…

WednesdayOct 15, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advances AI-Powered Breast CT Innovation and Reinforces Its Commitment to Safer, Smarter Cancer Imaging

Izotropic recently published a piece that explores the way AI is redefining breast imaging and the way the innovative IzoView system was designed for the future The company’s 3D breast CT platform helps tackle one of the major concerns of cancer screening: radiation exposure in CT imaging With its trade-secret reconstruction algorithm, AI-native design, and fair price model, IzoView strategically places Izotropic to dominate the future of breast imaging technology These latest updates further highlight Izotropic’s mission: to redefine breast diagnostics using innovation that prioritizes safety, precision, and accessibility Izotropic (CSE: IZO) (OTCQB: IZOZF) is changing how breast cancer imaging is…

MondayOct 13, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026

The closing of the public offering provides the company with critical financial flexibility as it continues to advance its pipeline of products. The $7.5 million raised through the public offering is particularly significant in the context of Soligenix’s ongoing clinical development programs. SNGX notes multiple potential value drivers over the next 18 months, including clinical milestones, regulatory interactions and data readouts across its pipeline. Soligenix (NASDAQ: SNGX) recently announced the closing of a $7.5 million public offering, providing the company with additional capital to advance its pipeline (https://ibn.fm/tCsub). This funding extends Soligenix’s cash runway through the end of 2026, ensuring…

FridayOct 10, 2025 11:15 am

Lantern Pharma Inc. (NASDAQ: LTRN) CEO Panna Sharma and New Board Member Dr. Lee Schalop Discuss How AI Can Reshape CNS Oncology Drug Development

Lantern’s RADR(R) AI platform is helping identify optimal indications and pathways for precision cancer therapies. Dr. Schalop reflects on lessons from developing ONC201, approved for H3K27M-mutant glioma, after a 16-year journey. Both leaders highlight the potential for AI to accelerate regulatory reviews and clinical trial design. The conversation underscores how AI could reduce oncology drug timelines and costs, improving patient access to new treatments, and how STAR-001, Lantern’s new CNS cancer drug, can benefit from these AI-driven insights. In oncology, the path from molecule discovery to patient treatment often stretches over a decade and can consume hundreds of millions of…

ThursdayOct 09, 2025 12:00 pm

Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL

The expansion of Soligenix’s European Medical Advisory Board underscores the company's commitment to delivering innovative treatment options to European patients. HyBryte (synthetic hypericin) is a first-in-class, photodynamic therapy using synthetic hypericin as a photosensitizer. The company’s efforts could establish HyBryte as a new standard of care for patients who currently have limited options. Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9 cases per million people (https://ibn.fm/ANk8X). Despite its rarity, CTCL presents a substantial…

WednesdayOct 08, 2025 11:15 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Expands Commercialization Strategy with $375K Financing, Investor Awareness Agreements, and Breakthrough Personalized Radiation Dose Breast CT

Izotropic Corp. marks a significant milestone in breast imaging with its patent-pending personalized radiation dose feature with the IzoView Breast CT system Recently, the company secured a $375,000 non-brokered private placement to help with core operations in addition to engaging new PR partners for improved investor communications With projections for global breast imaging expected to hit $8.69 billion by 2030, the company is poised to strategically dominate the market Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a leading medical device firm in the field of breast cancer imaging solutions, is speeding up its efforts towards commercializing its innovations. Izotropic recently…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium

Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Breast Cancer Awareness Month by Addressing Gaps in Screening and Advancing the IzoView Breast CT Solution

Nanomedicine’s Next Leap: Why Particle Size Matters in Cancer Drug Delivery

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advances AI-Powered Breast CT Innovation and Reinforces Its Commitment to Safer, Smarter Cancer Imaging

Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026

Lantern Pharma Inc. (NASDAQ: LTRN) CEO Panna Sharma and New Board Member Dr. Lee Schalop Discuss How AI Can Reshape CNS Oncology Drug Development

Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Expands Commercialization Strategy with $375K Financing, Investor Awareness Agreements, and Breakthrough Personalized Radiation Dose Breast CT

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search